Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASH 2017
ASH 2017
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
Conference Correspondent
The results of the Radius-X expanded treatment protocol showed a safety profile that was consistent with that previously described in patients with
FLT3
mutation–positive, newly diagnosed acute myeloid leukemia (AML).
Read Article
Ivosidenib Monotherapy in Patients with Relapsed/Refractory AML and Other Advanced Hematologic Malignancies
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
Conference Correspondent
Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML).
Read Article
Quizartinib plus Azacitidine or Low-Dose Cytarabine Is Active in FLT3-ITD–Mutated Myeloid Leukemias
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
Conference Correspondent
Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with
FLT3
-ITD–mutated myeloid leukemias.
Read Article
Venetoclax plus MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in R/R AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
Conference Correspondent
The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML).
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma